Skip to main content

Table 1 Clinical and biochemical characteristics of the subjects (n = 324)

From: Association of Alanine Aminotransferase Levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): a cross-sectional study

Variable

All subjects (n = 324)

Without metabolic abnormalities (n = 113)

Metabolic syndrome (n = 179)

IFG (n = 85)

IGT (n = 91)

Type 2 DM (n = 23)

Age (year)

40.4 ± 14.3

36.4 ± 13.5

42.1 ± 14.3a

47.3 ± 13.9b

46.4 ± 14.7c

48.8 ± 12.7d

Males (n, %)

122 (37.6)

38 (33.6)

70 (57.4)

34 (27.9)

39 (32.0)

10 (8.2)

Weight (kg)

84.8 ± 22.2

80.1 ± 18.8

89.1 ± 20.8a

86.2 ± 21.6b

86.0 ± 22.1c

86.3 ± 17.9

BMI (kg/m2)

32.0 ± 7.3

29.9 ± 6.6

33.9 ± 8.3a

33.2 ± 9.3b

33.4 ± 9.0c

32.8 ± 4.7

WC (cm)

103.9 ± 16.7

98.4 ± 16.5

108.1 ± 15.5a

105.9 ± 16.1b

107.3 ± 16.3c

107.0 ± 13.9d

M

105.2 ± 14.8

96.8 ± 15.3

110.1 ± 12.9a

108.6 ± 13.5b

110.2 ± 13.2c

110.9 ± 7.5d

F

103.1 ± 17.7

99.2 ± 17.2

106.8 ± 16.9a

104.1 ± 17.5

105.1 ± 18.1

104.0 ± 17.0

 p

0.26

0.48

0.16

0.20

0.14

0.24

SBP (mmHg)

118.6 ± 15.5

111.7 ± 12.4

123.2 ± 16.3a

124.3 ± 16.0b

124.2 ± 16.0c

131.3 ± 17.0d

DBP (mmHg)

77.7 ± 10.0

74.1 ± 9.8

80.1 ± 9.7a

79.3 ± 8.7b

79.9 ± 8.8c

81.6 ± 8.7d

ALT (IU/L)

26.0 (20.0-41.0)

22 (17.0-31.0)

27.0 (22.0-51.0)a

29.0 (22.0-60.0)b

31.0 (23.0-49.0)c

30.0 (24.0-61.0)d

M

33.0 (23.7-62.7)

29.0 (22.0-38.5)

40.0 (26.0-80.0)a

39.5 (26.0-79.2)b

33.0 (24.0-79.0)

34.5 (28.0-65.5)

F

23.0 (19.0-32.0)

20.0 (16–28)

25.0 (20.0-34.0)a

25.0 (21.0-38.0)b

29.0 (23.0-44.0)c

27.0 (23.0-55.0)

 p

<0.001

0.001

<0.001

0.003

0.13

0.20

AST (IU/L)

25.0 (21.0-35.0)

23.0 (19.0-29.0)

26.0 (22.0-38.-0)

27.0 (22.0-41.5)

29.0 (23.0-42.0)

27.0 (23.0-45.0)

M

28.5 (22.0-41.2)

26.5 (21.0-34.5)

30.5 (23.0-48.2)

31.5 (25.0-47.2)

31.0 (23.0-45.0)

29.5 (23.7-45.7)

F

23.0 (20.0-3.5)

21.0 (180–27.2)

25.0 (21.0-32.0)

26.0 (22.0-37.0)

29.0 (22.2-37.5)

26.0 (22.0-50.5)

 p

<0.001

0.005

0.001

0.074

0.455

0.832

TC (mg/dL)

189.0 ± 36.3

178.4 ± 36.5

195.9 ± 34.5a

197.0 ± 33.1b

191.4 ± 38.9c

190.5 ± 39.2

Triglycerides (mg/dL)

147.0 (108.7-201.5)

107.0 (75.7-131.0)

174.5 (149.7-245.2)a

163.0 (123.0-210.0)b

167.0 (121.0-236.5)c

170.5 (127.2-211.2)d

HDL-C (mg/dL)

37.7 ± 10.9

41.6 ± 12.6

34.7 ± 8.2a

37.1 ± 10.7b

35.2 ± 9.3c

30.6 ± 9.5d

M

32.5 ± 8.9

36.5 ± 10.5

30.9 ± 7.0a

32.1 ± 8.0

31.1 ± 8.1c

25.6 ± 4.4d

F

39.5 ± 11.0

44.4 ± 12.9

37.3 ± 8.0a

40.7 ± 11.0

38.1 ± 9.0c

35.6 ± 10.8d

 p

<0.001

0.003

<0.001

<0.001

0.001

0.01

Body fat (%)

38.1 ± 9.1

37.1 ± 9.5

39.2 ± 8.8a

38.2 ± 8.9

38.3 ± 8.8

38.8 ± 8.1

M

30.9 ± 7.2

28.6 ± 8.8

32.4 ± 5.9a

31.0 ± 6.3

31.8 ± 6.4

32.1 ± 4.6

F

42.4 ± 7.1

41.4 ± 6.5

43.6 ± 7.5a

43.0 ± 7.0

43.1 ± 7.2

44.0 ± 6.1

 p

<0.001

<0.001

<0.001

<0.001

<0.001

<0.001

FG (mg/dL)

93.7 ± 13.6

85.7 ± 8.1

98.2 ± 14.8a

110.3 ± 13.0b

104.8 ± 16.4c

123.0 ± 19.2d

Fasting insulin (μlU/mL)

10.8 (6.9-15.4)

7.3 (5.2-11.6)

12.8 (8.1-17.9)a

13.7 (9.2-18.6)b

13.4 (8.5-19.9)c

14.8 (7.0-21.6)d

HOMA-2IR

1.4 (0.9-2.0)

1.0 (0.7-1.5)

1.7 (1.1-2.4)a

1.8 (1.2-2.4)b

1.8 (1.1-2.6)c

2.1 (0.9-3.0)d

ISI Matsuda

3.5 (2.3-5.5)

5.5 (3.9-8.5)

2.8 (1.9-4.4)a

2.5 (1.5-3.4)b

2.5 (1.5-3.6)c

2.1 (1.4-3.6)d

HIRI

36.9 ± 12.1

33.1 ± 12.0

39.4 ± 11.9a

38.6 ± 12.4b

37.6 ± 10.3c

36.3 ± 10.9

  1. Data are expressed as mean ± SD (comparisons made with Student unpaired t-test), median [(interquartil range), comparisons made with Mann–Whitney U test], or frequency [(%) comparisons made with the Pearson chi square] BMI = body mass index, WC = waist circumference, SBP = systolic blood pressure, DBP = diastolic blood pressure, ALT = alanine aminotransferase, AST = aspartate aminotransferase, TC = total cholesterol, HDL-C = high density lipoprotein cholesterol, FG = fasting glucose, HOMA2-IR = Homeostasis Model Assessment Insulin Resistance 2, ISI = Insulin Sensitivity Index, and HIRI = Hepatic Insulin Resistance Index.
  2. a = p < 0.05 between subjects without metabolic abnormalities and MetS.
  3. b = p < 0.05 between subjects without metabolic abnormalities and IFG.
  4. c = p < 0.05 between subjects without metabolic abnormalities and IGT.
  5. d = p < 0.05 between subjects without metabolic abnormalities and T2DM.
  6. The total number of subjects is different of 324, because, 40% (n = 73) of subjects with MetS have IFG, 36% (n = 66) of subjects with MetS have IGT, and 11% of subjects (n = 20) of subjects with MetS have DM2.